 |
| Main Menu | News By Date | News By Supplier | News By Category | About Us |
|
BTG & THE GENERICS GROUP COMBINE KEY PATENTS & GRANT LICENCE FOR DEVELOPMENT OF NEW BIO-CHIP TECHNOLOGY
BTG, the global technology commercialisation company, announced today that it has worked with The Generics Group, the technology consulting, development and investment organisation, to create the potential for a new bio-chip technology. Together they are licensing a patent portfolio in electronics and the life sciences to Aura Oncology Systems Inc., which could lead to a bio-chip technology that could assist in the diagnosis of cancer and the development of new oncology drugs. The technologies, which are based on 'dielectrophoresis', were developed by Professor Ronald Pethig and colleagues at the University College Bangor, North Wales, UK, in collaboration with Aura Oncology. These technologies have a potential role in the fast-developing field of cell biology, relating to the development of treatments for cancer. They work by marrying microelectronics and biology to provide a next generation of processing and diagnostic tools for research and clinical applications. Bio-separation devices made of microelectronic arrays controlled by AC (alternating current) voltages, are used to identify and separate of biological particles, such as cells, viruses and protein molecules. Anthony Lando, Executive VP and Divisional Director of BTG said: "By working with The Generics Group, we were able to combine our own patents in electronics and medical science with those of Professor Pethig, creating a unique portfolio. This platform allows Aura Oncology to accelerate its research into the use of bio-chip technology in the fields of drug discovery and cell biology."
|
| ©2008 New Materials International |